Table 3.

Confirmatory testing results. The data are expressed as medians and ranges. Group A patients underwent two identical confirmatory tests under RAAS-neutral therapy conditions. Group B patients underwent two confirmatory tests: the first with modified chronic antihypertensive therapy and the second with RAAS-neutral therapy.

	Group A (51 patients)		Group B (53 patients)
	Test 1a,b	Test 2a,b	Test 1c	Test 2a
Aldosterone-to-renin ratiod,e	45.7 (0.7–204.5)	47.0 (1.4–160.4)	61 (14–896)	62 (11–564)
Serum potassium level (mmol/l)f	3.7 (2.7–4.6)	3.7 (2.9–4.7)	3.9 (2.7–4.8)	3.8 (2.6–4.7)
Urinary sodium excretion (mmol/24 h)f	368 (124–814)	358 (142–721)	405 (60–776)	385 (90–704)
Plasma active renin after 2 h of bed rest (ng/l)	2.7 (2.7–10.8)	2.7 (2.7–7.4)	2.7 (2.7–38.8)	2.7 (2.7–43.2)
Serum aldosterone after 2 h of bed rest (pmol/l)	100 (30–1900)	160 (40–1880)	250 (50–1780)	255 (50–1230)
Plasma active renin at the end of saline infusion (ng/l)	2.7 (2.7–6.9)	2.7 (2.7–5.4)	2.7 (2.7–7.9)	2.7 (2.7–5.1)
Serum aldosterone at the end of saline infusion (pmol/l)	140 (30–2400)	160 (30–2020)	165 (40–1280)	165 (30–1330)
Systolic blood pressure (mmHg)g	150 (120–192)	158 (116–196)	150 (118–220)	164 (115–218)
Diastolic blood pressure (mmHg)g	92 (70–118)	94 (70–122)	90 (70–120)	95 (70–110)

^aConfirmatory tests performed under RAAS-neutral therapy, only doxazosin and/or verapamil were allowed.

^bConfirmatory tests performed with identical dosing of doxazosin and/or verapamil.

^cConfirmatory tests performed under modified chronic antihypertensive therapy conditions, aldosterone antagonists and diuretics were withdrawn before testing.

^dBlood sampling was performed after oral sodium loading before the saline infusion was given.

^eTo calculate the aldosterone-to-renin ratio, both aldosterone and renin were expressed in nanograms per liter.

^fA 24-h urine sample was collected the day before the saline infusion was administered.

^gBlood pressure measurement after saline infusion.